Valuation : Cerus Corporation

Market Cap 534M 460M 432M 394M 740M 50.81B 746M 5.12B 1.99B 25.77B 2.01B 1.96B 85.32B P/E 2026 *
-75.3x
P/E 2027 * -264x
Enterprise Value 539M 464M 436M 398M 747M 51.29B 753M 5.16B 2.01B 26.01B 2.02B 1.98B 86.12B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 1.92x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day-0.38%
1 week-1.86%
Current month+22.79%
1 month+22.79%
3 months-7.04%
6 months+23.94%
Current year+28.16%
1 week 2.56
Extreme 2.56
2.79
1 month 2.06
Extreme 2.065
3.08
Current year 1.62
Extreme 1.62
3.47
1 year 1.17
Extreme 1.17
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

General Counsel

-30,000 0.0150%
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%-1.86%+107.87%+39.68% 534M
-2.08%-1.71%-17.27%+12.77% 127B
-0.93%-0.65%-23.17%-1.07% 12.12B
-0.17%-2.88%+87.39%+137.17% 10.6B
-1.36%+0.49%-52.15%-70.60% 4.22B
-7.30%-5.27%-23.88%+39.09% 2.72B
-2.28%-3.04% - - 2.04B
+2.52%+1.01%-32.77%-73.48% 1.78B
-1.69%-3.85%-18.12%-18.55% 1.62B
Average -1.44%-2.64%+3.49%+8.13% 18.05B
Weighted average by Cap. -1.30%-0.17%-11.59%+17.02%

Financials

2026 *2027 *
Net sales 249M 214M 201M 184M 345M 23.7B 348M 2.39B 928M 12.02B 935M 915M 39.79B 272M 234M 220M 200M 376M 25.84B 379M 2.6B 1.01B 13.1B 1.02B 997M 43.38B
Net income -8.77M -7.55M -7.09M -6.47M -12.15M -834M -12.24M -83.98M -32.68M -423M -32.92M -32.2M -1.4B -1.67M -1.44M -1.35M -1.23M -2.31M -159M -2.33M -15.97M -6.21M -80.41M -6.26M -6.12M -266M
Net Debt 5M 4.3M 4.04M 3.69M 6.93M 476M 6.98M 47.9M 18.64M 241M 18.77M 18.37M 799M -13M -11.19M -10.51M -9.59M -18.02M -1.24B -18.15M -125M -48.45M -627M -48.81M -47.75M -2.08B
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-08-31 $2.640 -0.38% 1,321,133
26-08-28 $2.650 -2.57% 1,683,565
26-08-27 $2.720 -0.73% 810,572
26-08-26 $2.740 +0.74% 1,103,083
26-08-25 $2.720 +1.12% 831,204
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.650USD
Average target price
5.125USD
Spread / Average Target
+93.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock